Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers.

Gagnon B, Agulnik JS, Gioulbasanis I, Kasymjanova G, Morris D, MacDonald N.

Br J Cancer. 2013 Oct 15;109(8):2066-71. doi: 10.1038/bjc.2013.515. Epub 2013 Sep 24.

2.

Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.

Shi Y, Chen L, Li J, Lv YL, Sun Q, Wang LX, Jiao SC.

Tumour Biol. 2011 Apr;32(2):381-90. doi: 10.1007/s13277-010-0131-8. Epub 2010 Nov 18.

PMID:
21086091
3.

Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.

Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C.

Lung Cancer. 2012 Jul;77(1):116-20. doi: 10.1016/j.lungcan.2012.01.013. Epub 2012 Feb 21.

PMID:
22361218
4.

99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.

Yüksel M, Cermik TF, Doğanay L, Karlikaya C, Cakir E, Salan A, Berkarda S.

Eur J Nucl Med Mol Imaging. 2002 Jul;29(7):876-81. Epub 2002 Apr 26.

PMID:
12111127
6.

High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.

Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, Yang HX.

Eur J Surg Oncol. 2012 Jun;38(6):523-30. doi: 10.1016/j.ejso.2012.02.180. Epub 2012 Mar 21.

PMID:
22440742
7.

Prognostic impact of Raf-1 and p-Raf-1 expressions for poor survival rate in non-small cell lung cancer.

Qiu ZX, Wang L, Han J, Liu D, Huang W, Altaf K, Qiu XS, Javed MA, Zheng J, Chen BJ, Li WM.

Cancer Sci. 2012 Oct;103(10):1774-9. doi: 10.1111/j.1349-7006.2012.02375.x. Epub 2012 Aug 8.

8.

Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer.

Zhu WY, Hunag YY, Liu XG, He JY, Chen DD, Zeng F, Zhou JH, Zhang YK.

Anat Rec (Hoboken). 2012 Feb;295(2):208-14. doi: 10.1002/ar.21523. Epub 2011 Dec 21.

9.

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN.

BMC Cancer. 2010 May 9;10:186. doi: 10.1186/1471-2407-10-186.

10.

High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer.

Zhou H, Chen JH, Hu J, Luo YZ, Li F, Xiao L, Zhong MZ.

J Cancer Res Clin Oncol. 2014 Apr;140(4):633-43. doi: 10.1007/s00432-014-1616-4. Epub 2014 Feb 19.

PMID:
24549739
11.

Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.

Pelletier MP, Edwardes MD, Michel RP, Halwani F, Morin JE.

Can J Surg. 2001 Jun;44(3):180-8.

12.

[Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].

Li Y, Sun BS, Zhang ZF, Zhang LM, Wang CL.

Zhonghua Yi Xue Za Zhi. 2011 Jun 28;91(24):1682-6. Chinese.

PMID:
21914316
13.

Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, Zhong R, Xu Y, Wu J, Yu D, Wu T, Zhang X, Nie S, Miao X, Lin D.

Lung Cancer. 2011 Jul;73(1):110-5. doi: 10.1016/j.lungcan.2010.11.004. Epub 2010 Dec 3.

PMID:
21129812
14.

Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.

Takagi Y, Toriihara A, Nakahara Y, Yomota M, Okuma Y, Hosomi Y, Shibuya M, Okamura T.

PLoS One. 2013;8(3):e59700. doi: 10.1371/journal.pone.0059700. Epub 2013 Mar 26.

15.

Prognostic factors in older patients with advanced non-small cell lung cancer in China.

Su Q, Sun YP, Liu YH, Li Z, Yang HY, Sun ZG, Cao BW, Jia JH.

Tumori. 2014 Jan-Feb;100(1):69-74. doi: 10.1700/1430.15818.

PMID:
24675494
16.

Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection.

Jiang W, Pang XG, Wang Q, Shen YX, Chen XK, Xi JJ.

Clin Lung Cancer. 2012 Jul;13(4):280-7. doi: 10.1016/j.cllc.2011.11.005. Epub 2011 Dec 16.

PMID:
22178381
17.

ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.

Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q.

Mol Biol Rep. 2012 Jun;39(6):6933-42. doi: 10.1007/s11033-012-1520-4.

PMID:
22302397
18.

Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.

Yang J, Ramnath N, Moysich KB, Asch HL, Swede H, Alrawi SJ, Huberman J, Geradts J, Brooks JS, Tan D.

BMC Cancer. 2006 Aug 1;6:203.

19.

Tumor cavitation among lung cancer patients receiving first-line chemotherapy at a tertiary care centre in India: association with histology and overall survival.

Singh N, Mootha VK, Madan K, Aggarwal AN, Behera D.

Med Oncol. 2013;30(3):602. doi: 10.1007/s12032-013-0602-z. Epub 2013 May 15.

PMID:
23673987
20.

HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.

Zhang J, Chen N, Qi J, Zhou B, Qiu X.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1441-9. doi: 10.1007/s00432-014-1687-2. Epub 2014 Apr 27.

PMID:
24770635
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk